POMHEX
Based on 4 publication(s) in Google Scholar
POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) proagent of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.54%
- No. CAS: 2004714-34-3
- Fòrmula: C17H30NO9P
- Peso molecular:423.40
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Glycolysis Compound Library
HY-L058
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) POMHEX
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| D-423MG | IC50 |
1184 nM
Compound: 6; POMHEX
|
Cytotoxicity against human D-423MG cells expressing ENO1 assessed as cell growth inhibition incubated for 6 days by cystal violet staining based analysis
Cytotoxicity against human D-423MG cells expressing ENO1 assessed as cell growth inhibition incubated for 6 days by cystal violet staining based analysis
|
[PMID: 36251833] |
| D-423MG | IC50 |
17.3 nM
Compound: POMHEX
|
Cytotoxicity against human D423 cells with ENO1 deficient assessed as reduction in cell viability incubated for 5 days by crystal violet staining based spectrophotometry
Cytotoxicity against human D423 cells with ENO1 deficient assessed as reduction in cell viability incubated for 5 days by crystal violet staining based spectrophotometry
|
[PMID: 33130289] |
| D-423MG | IC50 |
29 nM
Compound: 6; POMHEX
|
Cytotoxicity against human D-423MG cells assessed as cell growth inhibition incubated for 6 days by cystal violet staining based analysis
Cytotoxicity against human D-423MG cells assessed as cell growth inhibition incubated for 6 days by cystal violet staining based analysis
|
[PMID: 36251833] |
POMHEX (78 nM, 8h) minimally impacts ENO1-WT glioma cells but profoundly affected ENO1-deleted cells[1].
?
POMHEX (0-720 nM) selectively induces energy stress, inhibits proliferation and triggers apoptosis in ENO1-deleted glioma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ENO1-deleted (D423, red), ENO1-isogenically rescued (D423 ENO1, blue) and ENO1-WT (LN319, grey) cells.
-
Concentration:78 nM.
-
Incubation Time:8 h.
-
Result:Down-regulated cell density.
? POMHEX is rapidly hydrolysed to HemiPOMHEX in mouse plasma ex vivo, with a half-life of approximately 30 s, the half-life in human blood ex vivo was about 9min[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2004714-34-3
-
Appearance Solid
-
Peso molecular 423.40
-
Fòrmula C17H30NO9P
-
Color White to light yellow
-
SMILES
O=P(OCOC(C(C)(C)C)=O)(OCOC(C(C)(C)C)=O)C1C(N(O)CCC1)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
Mitochondrial-Encoded Complex I Impairment Induces a Targetable Dependency on Aerobic Fermentation in Hürthle Cell Carcinoma of the Thyroid. [Abstract]2023 Aug 4;13(8):1884-1903. PMID: 37262072 -
Nat Chem Biol
2025 Jan;21(1):91-99. PMID: 39030363 -
Proc Natl Acad Sci U S A
2025 Mar 11;122(10):e2404899122. PMID: 40030031 -
Biomedicines
HIF-1α Promotes Macrophage Extracellular Trap Formation and Exacerbates Acute Lung Injury in Neonatal Sepsis. [Abstract]2026 May 18;14(5):1145. PMID: 42193470
Solvente y solubilidad
DMSO : 100 mg/mL (236.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3618 mL | 11.8092 mL | 23.6183 mL | 59.0458 mL |
| 5 mM | 0.4724 mL | 2.3618 mL | 4.7237 mL | 11.8092 mL | |
| 10 mM | 0.2362 mL | 1.1809 mL | 2.3618 mL | 5.9046 mL | |
| 15 mM | 0.1575 mL | 0.7873 mL | 1.5746 mL | 3.9364 mL | |
| 20 mM | 0.1181 mL | 0.5905 mL | 1.1809 mL | 2.9523 mL | |
| 25 mM | 0.0945 mL | 0.4724 mL | 0.9447 mL | 2.3618 mL | |
| 30 mM | 0.0787 mL | 0.3936 mL | 0.7873 mL | 1.9682 mL | |
| 40 mM | 0.0590 mL | 0.2952 mL | 0.5905 mL | 1.4761 mL | |
| 50 mM | 0.0472 mL | 0.2362 mL | 0.4724 mL | 1.1809 mL | |
| 60 mM | 0.0394 mL | 0.1968 mL | 0.3936 mL | 0.9841 mL | |
| 80 mM | 0.0295 mL | 0.1476 mL | 0.2952 mL | 0.7381 mL | |
| 100 mM | 0.0236 mL | 0.1181 mL | 0.2362 mL | 0.5905 mL |
POMHEX Related Classifications
HY-131904 Related Classifications
Powered by Bioz